NCT03566810View on ClinicalTrials.gov

Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

November 28, 2018

Study Completion Date

November 28, 2018

Conditions
Healthy
Interventions
DRUG

Test GXR

Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

DRUG

Reference GXR

Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Trial Locations (1)

Unknown

Xuanwu Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03566810 - Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt) | Biotech Hunter | Biotech Hunter